Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Cash from Financing Activities (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Cash from Financing Activities for 12 consecutive years, with $253000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Financing Activities changed N/A year-over-year to $253000.0, compared with a TTM value of $96.1 million through Sep 2025, up 1641.02%, and an annual FY2024 reading of $7.5 million, down 75.12% over the prior year.
  • Cash from Financing Activities was $253000.0 for Q3 2025 at CytomX Therapeutics, down from $93.6 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $108.7 million in Q1 2021 and bottomed at $7000.0 in Q1 2022.
  • Average Cash from Financing Activities over 5 years is $16.2 million, with a median of $451000.0 recorded in 2022.
  • The sharpest move saw Cash from Financing Activities skyrocketed 4941.03% in 2021, then tumbled 99.99% in 2022.
  • Year by year, Cash from Financing Activities stood at $683000.0 in 2021, then tumbled by 72.18% to $190000.0 in 2022, then rose by 28.42% to $244000.0 in 2023, then surged by 821.72% to $2.2 million in 2024, then tumbled by 88.75% to $253000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for CTMX at $253000.0 in Q3 2025, $93.6 million in Q2 2025, and $2.2 million in Q4 2024.